Twist Bioscience Co. (NASDAQ:TWST – Get Free Report) COO Patrick John Finn sold 2,681 shares of the business’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $111,422.36. Following the completion of the transaction, the chief operating officer now owns 237,640 shares of the company’s stock, valued at approximately $9,876,318.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Patrick John Finn also recently made the following trade(s):
- On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The stock was sold at an average price of $43.09, for a total value of $97,426.49.
- On Wednesday, October 2nd, Patrick John Finn sold 6,865 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total value of $296,636.65.
Twist Bioscience Stock Performance
NASDAQ TWST opened at $45.42 on Thursday. The company has a market cap of $2.66 billion, a P/E ratio of -11.89 and a beta of 1.78. The business’s 50 day moving average price is $43.64 and its 200-day moving average price is $45.43. Twist Bioscience Co. has a fifty-two week low of $15.85 and a fifty-two week high of $60.90.
Institutional Investors Weigh In On Twist Bioscience
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on TWST shares. Leerink Partners raised their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Barclays lowered their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Robert W. Baird lifted their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. JPMorgan Chase & Co. upped their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. Finally, Evercore ISI raised their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $51.22.
Check Out Our Latest Analysis on TWST
Twist Bioscience Company Profile
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Further Reading
- Five stocks we like better than Twist Bioscience
- Where Do I Find 52-Week Highs and Lows?
- Top 3 Sectors Outperforming After Trump’s Victory
- How to Calculate Stock Profit
- Sono-Tek’s $2M Buyback: A Buying Opportunity in Clean Tech
- The Most Important Warren Buffett Stock for Investors: His Own
- MGM vs. Las Vegas Sands: Which Casino Stock Is the Better Bet?
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.